FGL2 and cystic fibrosis: However, our results in CF patient organoids were more complex, since FGL2 knockdown apparently did not significantly affect the activity of Trikafta‐rescued F508del‐CFTR in 3D organoids (as measured in the FIS assay) but lead to a substantial increase in activity in 2D monolayers (as measured in using Ussing chamber).